SREBF1 and metabolic dysfunction-associated steatotic liver disease: The present study first demonstrated that RTLW may decrease DNL via downregulating SREBP1 and FAS expressions in liver, while inhibiting the accumulation of hepatic TG and formation of NAFLD in HFD/STZ‐induced diabetic rats.